

Immunotherapy approvals and current use of first-line immunotherapy (as of June 3, 2020)

Recent approvals are bolded in the table

Level of PD-L1 expression	Choice of immunotherapy for first-line treatment of NSCLC
No PD-L1 expression	<ul style="list-style-type: none"> • Chemotherapy-pembrolizumab combination for both squamous/nonsquamous NSCLC • Chemotherapy-atezolizumab-bevacizumab for nonsquamous NSCLC • Chemotherapy-atezolizumab for nonsquamous NSCLC • Limited chemotherapy (2 cycles)- ipililumab-nivolumab for both squamous/nonsquamous NSCLC (May 2020)
PD-L1 expression greater than or equal to 1%	<ul style="list-style-type: none"> • Chemotherapy-pembrolizumab combination for both squamous/nonsquamous NSCLC • Pembrolizumab for both squamous/non-squamous • Chemotherapy-atezolizumab-bevacizumab for nonsquamous NSCLC • Chemotherapy-atezolizumab for nonsquamous NSCLC • Limited chemotherapy (2 cycles)- ipililumab-nivolumab for both squamous/nonsquamous NSCLC (May 2020) • Ipililumab-nivolumab for both squamous/nonsquamous NSCLC (May 2020)
PD-L1 expression greater than or equal to 50%	<ul style="list-style-type: none"> • Pembrolizumab for both squamous/nonsquamous NSCLC • Atezolizumab for both squamous/nonsquamous NSCLC (May 2020) • Ipililumab-nivolumab for both squamous/nonsquamous NSCLC (May 2020)

**Non-smoker with no driver mutation
(irrespective of PD-L1 status)**

- Chemotherapy-pembrolizumab combination for both squamous/nonsquamous NSCLC
- Chemotherapy-atezolizumab-bevacizumab for nonsquamous NSCLC
- Chemotherapy-atezolizumab- for nonsquamous NSCLC
- **Limited chemotherapy (2 cycles)- ipililumab-nivolumab for both squamous/nonsquamous NSCLC (May 2020)**